Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.
Omeprazole is an inhibitor of gastric H+,K(+)-ATPase. Although the major proton transport of osteoclast is mediated by a vacuolar-type H(+)-ATPase which is different from the gastric H+,K(+)-ATPase, in vitro studies have demonstrated that omeprazole inhibits bone resorption. In this study, the effect of omeprazole on bone resorption was evaluated in patients who had a history of gastric ulcer and were treated with maintenance doses of H2 blocker without any gastric complaints at the study time. H2-blocker administration was changed to omeprazole treatment in the study group and to no treatment in the control group. Urinary excretion of hydroxyproline and calcium decreased after omeprazole treatment in the study group. Serum intact PTH, alkaline phosphatase, osteocalcin, and tartrate-resistant acid phosphatase (TRAP) increased in this group. In the control group, there were not any changes in these parameters. The discrepancy between serum TRAP and urinary excretion of hydroxyproline and calcium in the study group was thought to be due to the suppression of bone resorption by omeprazole, which probably interfered the acidification at resorption lacunae and resulted in the inactivation of TRAP and other lysosomal enzymes. The results of our study suggest the possibility that the specific inhibitors of the osteoclastic proton pump (such as bafilomycins) will more effectively suppress bone resorption and be useful for the treatment of metabolic bone diseases with increased bone resorption.
Mizunashi
K
K
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Furukawa
Y
Y
Katano
K
K
Abe
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001835:Body Weight / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy*; D002118:Calcium / Q000097:blood / Q000652:urine; D002648:Child; D002927:Cimetidine / Q000494:pharmacology; D005260:Female; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000494:pharmacology* / Q000627:therapeutic use; D015675:Osteocalcin / Q000097:blood; D010880:Piperidines / Q000494:pharmacology; D054328:Proton Pump Inhibitors; D013276:Stomach Ulcer / Q000188:drug therapy
D015415:Biomarkers; D006635:Histamine H2 Antagonists; D010880:Piperidines; D054328:Proton Pump Inhibitors; D015675:Osteocalcin; D002927:Cimetidine; D000469:Alkaline Phosphatase; D009853:Omeprazole; D006909:Hydroxyproline; D002118:Calcium; C053742:roxatidine acetate